HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms

Targeting Myristoylated Alanine-Rich C Kinase Substrate Phosphorylation Site Domain in Lung Cancer. Mechanisms and Therapeutic Implications

(2014) Ching-Hsien Chen et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cancer treatment and survivorship statistics, 2014

(2014) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tid1-L Inhibits EGFR Signaling in Lung Adenocarcinoma by Enhancing EGFR Ubiquitinylation and Degradation

(2013) Chi-Yuan Chen et al.   CANCER RESEARCH

Progress towards the development of SH2 domain inhibitors

(2013) Dziyana Kraskouskaya et al.   CHEMICAL SOCIETY REVIEWS

Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung

(2013) Andrew M. Brunner et al.   Journal of Thoracic Oncology

Chaperone machines for protein folding, unfolding and disaggregation

(2013) Helen Saibil   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas

(2013) C. E. Chee et al.   ONCOLOGIST

Src activation by β-adrenoreceptors is a key switch for tumour metastasis

(2013) Guillermo N. Armaiz-Pena et al.   Nature Communications

DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin

(2012) A Mitra et al.   ONCOGENE

Human DNAJ in cancer and stem cells

(2011) Jason N. Sterrenberg et al.   CANCER LETTERS

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

(2011) Siyuan Zhang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Tumor Suppressor HLJ1 Binds and Functionally Alters Nucleophosmin via Activating Enhancer Binding Protein 2  Complex Formation

(2010) T.-P. Chang et al.   CANCER RESEARCH

Src Inhibitors in Lung Cancer: Current Status and Future Directions

(2010) Sacha I. Rothschild et al.   Clinical Lung Cancer

Acidic stress facilitates tyrosine phosphorylation of HLJ1 to associate with actin cytoskeleton in lung cancer cells

(2010) Ching-Hsien Chen et al.   EXPERIMENTAL CELL RESEARCH

DNAJB6 Induces Degradation of β-Catenin and Causes Partial Reversal of Mesenchymal Phenotype

(2010) Aparna Mitra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

The dual kinase complex FAK-Src as a promising therapeutic target in cancer

(2010) Victoria Bolós   OncoTargets and Therapy

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Multi-faceted role of HSP40 in cancer

(2009) Aparna Mitra et al.   CLINICAL & EXPERIMENTAL METASTASIS

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer

(2009) B Y Ahn et al.   ONCOGENE

The Lipid Raft-Anchored Adaptor Protein Cbp Controls the Oncogenic Potential of c-Src

(2008) Chitose Oneyama et al.   MOLECULAR CELL